Nivolumab (Opdiva) receives accelerated approval from the Food and Drug Administration (FDA) for the treatment of Hodgkin lymphoma patients. More >
Welcome to Focus on HL
The FocusOnHL.org website is designed to provide helpful information and resources to patients, caregivers, physicians, and others affected by Hodgkin lymphoma.
We invite you to browse the website to learn more about Hodgkin lymphoma.
Getting the Facts
Lymphoma is the most common form of blood cancer. The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma. Hodgkin lymphoma is the less common of the two. According to the National Cancer Institute, approximately 8,500 new cases of Hodgkin lymphoma are projected each year.
Research into Hodgkin lymphoma has led to significant advancements in the understanding of the disease. Research continues on multiple fronts to develop better treatments for patients. We hope you will find the information presented here useful in understanding your disease and discussing it with your healthcare team.